Ravi K Amaravadi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5156769/publications.pdf

Version: 2024-02-01

115	26,213	18465	22147
papers	citations	62 h-index	113 g-index

119	119	119	38580
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma. Clinical Cancer Research, 2022, 28, 1098-1106.	3.2	32
2	ICAM-1-mediated adhesion is a prerequisite for exosome-induced TÂcell suppression. Developmental Cell, 2022, 57, 329-343.e7.	3.1	42
3	Clinical trial results show promise of targeting autophagy BRAF mutant melanoma. Autophagy, 2022, 18, 1470-1471.	4.3	7
4	Human epigenetic and transcriptional TÂcell differentiation atlas for identifying functional TÂcell-specific enhancers. Immunity, 2022, 55, 557-574.e7.	6.6	47
5	Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. Oncologist, 2022, 27, 716-e689.	1.9	5
6	Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. Oncologist, 2022, 27, 799-808.	1.9	3
7	Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. Journal of the National Cancer Institute, 2021, 113, 162-170.	3.0	81
8	Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Prostate Cancer and Prostatic Diseases, 2021, 24, 448-456.	2.0	0
9	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. JAMA Internal Medicine, 2021, 181, 195.	2.6	168
10	A Case of Tumor-Induced Osteomalacia: Finding the Culprit Acetabular Tumor and Successful Resection with a Novel Hip Joint-Preserving Surgery. Journal of Orthopaedic Case Reports, 2021, 11, 37-41.	0.1	0
11	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 2021, 12, 2349.	5.8	194
12	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 TÂcells. Cell Reports, 2021, 35, 109120.	2.9	60
13	Dichotomous and stable gamma delta T-cell number and function in healthy individuals. , 2021, 9, e002274.		13
14	Autophagy in major human diseases. EMBO Journal, 2021, 40, e108863.	3.5	615
15	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Research, 2021, 81, 5230-5241.	0.4	9
16	Anticancer properties of bisaminoquinolines with modified linkers. Bioorganic and Medicinal Chemistry Letters, 2021, 49, 128272.	1.0	2
17	Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer. International Journal of Molecular Sciences, 2021, 22, 12402.	1.8	8
18	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagyâ€mediated drug resistance in ovarian cancer cells, xenografts, and patientâ€derived xenograft models. Cancer, 2020, 126, 894-907.	2.0	54

#	Article	IF	Citations
19	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. Annals of Surgical Oncology, 2020, 27, 2915-2926.	0.7	11
20	Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell, 2020, 77, 633-644.e5.	4.5	45
21	Regulation of autophagy by canonical and non-canonical ER stress responses. Seminars in Cancer Biology, 2020, 66, 116-128.	4.3	120
22	SIRT1 is downregulated by autophagy in senescence and ageing. Nature Cell Biology, 2020, 22, 1170-1179.	4.6	236
23	Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves antiâ€“PD-1/PD-L1 immunotherapy. Science Advances, 2020, 6, eaax7881.	4.7	164
24	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clinical Cancer Research, 2020, 26, 3126-3134.	3.2	133
25	Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. Cell Reports, 2020, 33, 108571.	2.9	99
26	Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Immunity, 2020, 52, 825-841.e8.	6.6	497
27	PPT1 inhibition enhances the antitumor activity of antiâ€“PD-1 antibody in melanoma. JCI Insight, 2020, 5, .	2.3	44
28	TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature, 2019, 571, 211-218.	13.7	934
29	ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression. Nature Cell Biology, 2019, 21, 889-899.	4.6	157
30	Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies. Annals of Surgical Oncology, 2019, 26, 4621-4630.	0.7	10
31	Targeting Autophagy in Cancer: Recent Advances and Future Directions. Cancer Discovery, 2019, 9, 1167-1181.	7.7	579
32	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature Medicine, 2019, 25, 454-461.	15.2	466
33	A Potent Autophagy Inhibitor (Lys05) Enhances the Impact of Ionizing Radiation on Human Lung Cancer Cells H1299. International Journal of Molecular Sciences, 2019, 20, 5881.	1.8	17
34	Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia, 2019, 33, 981-994.	3.3	99
35	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discovery, 2019, 9, 396-415.	7.7	71
36	PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer. Cancer Discovery, 2019, 9, 220-229.	7.7	164

#	Article	IF	Citations
37	NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. Journal of Cutaneous Pathology, 2019, 46, 190-194.	0.7	6
38	Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. Clinical Cancer Research, 2019, 25, 2080-2087.	3.2	93
39	FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA. Retina, 2019, 39, 502-513.	1.0	27
40	Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role?. Cancer Discovery, 2018, 8, 266-268.	7.7	3
41	Targeting autophagy in cancer. Cancer, 2018, 124, 3307-3318.	2.0	484
42	Coâ€targeting <scp>BET</scp> and <scp>MEK</scp> as salvage therapy for <scp>MAPK</scp> and checkpoint inhibitorâ€resistant melanoma. EMBO Molecular Medicine, 2018, 10, .	3.3	79
43	Lysosomes Support the Degradation, Signaling, and Mitochondrial MetabolismÂNecessary for Human Epidermal Differentiation. Journal of Investigative Dermatology, 2018, 138, 1945-1954.	0.3	48
44	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research, 2018, 24, 4771-4784.	3.2	29
45	A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600â€Mutant Solid Tumors. Clinical Cancer Research, 2018, 24, 22-32.	3.2	30
46	Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Molecular and Cellular Oncology, 2018, 5, e1395504.	0.3	18
47	Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. JAMA Oncology, 2018, 4, 126.	3.4	8
48	Feasibility of monitoring advanced melanoma patients using cellâ€free <scp>DNA</scp> from plasma. Pigment Cell and Melanoma Research, 2018, 31, 73-81.	1.5	25
49	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1468956.	2.1	88
50	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research, 2018, 24, 5347-5356.	3.2	253
51	Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. Radiology, 2017, 283, 702-710.	3.6	43
52	Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma. Molecular Cancer Research, 2017, 15, 250-258.	1.5	52
53	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017, 545, 60-65.	13.7	1,280
54	Targeting the unfolded protein response in cancer. Pharmacological Research, 2017, 120, 258-266.	3.1	93

#	Article	IF	Citations
55	Lysosomal Biology in Cancer. Methods in Molecular Biology, 2017, 1594, 293-308.	0.4	68
56	Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation. Cancer Research, 2017, 77, 2869-2880.	0.4	17
57	Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma. Haematologica, 2017, 102, e261-e265.	1.7	17
58	ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells. Autophagy, 2017, 13, 2056-2071.	4.3	23
59	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 2017, 550, 133-136.	13.7	146
60	A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discovery, 2017, 7, 1266-1283.	7.7	159
61	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports, 2017, 21, 1936-1952.	2.9	72
62	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	2.9	117
63	CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nature Communications, 2017, 8, 15916.	5.8	214
64	Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors. International Journal of Molecular Sciences, 2017, 18, 1279.	1.8	293
65	Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma. Oncotarget, 2017, 8, 115140-115152.	0.8	9
66	Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 3545-3545.	0.8	16
67	Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. Molecular Carcinogenesis, 2016, 55, 1526-1541.	1.3	20
68	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell, 2016, 167, 1540-1554.e12.	13.5	830
69	Recent insights into the function of autophagy in cancer. Genes and Development, 2016, 30, 1913-1930.	2.7	641
70	Methods for Studying Autophagy Within the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2016, 899, 145-166.	0.8	38
71	Targeting the lysosome in cancer. Annals of the New York Academy of Sciences, 2016, 1371, 45-54.	1.8	221
72	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. Oncologist, 2016, 21, 84-94.	1.9	20

#	Article	IF	Citations
73	HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Research, 2016, 76, 2720-2730.	0.4	33
74	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer, 2015, 51, 1435-1443.	1.3	61
75	BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical Cancer Research, 2015, 21, 1652-1664.	3.2	106
76	Autophagy in malignant transformation and cancer progression. EMBO Journal, 2015, 34, 856-880.	3.5	1,012
77	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature, 2015, 520, 373-377.	13.7	1,955
78	A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Molecular Cancer Therapeutics, 2015, 14, 2569-2575.	1.9	98
79	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical Cancer Research, 2015, 21, 5215-5221.	3.2	17
80	Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy, 2015, 11, 60-74.	4.3	101
81	Transcriptional regulation of autophagy in RAS-driven cancers. Journal of Clinical Investigation, 2015, 125, 1393-1395.	3.9	7
82	Combined MTOR and autophagy inhibition. Autophagy, 2014, 10, 1391-1402.	4.3	366
83	Combined autophagy and HDAC inhibition. Autophagy, 2014, 10, 1403-1414.	4.3	240
84	A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy, 2014, 10, 1359-1368.	4.3	441
85	Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy, 2014, 10, 1415-1425.	4.3	149
86	Combined autophagy and proteasome inhibition. Autophagy, 2014, 10, 1380-1390.	4.3	310
87	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy, 2014, 10, 1369-1379.	4.3	309
88	Mouse Models Address Key Concerns Regarding Autophagy Inhibition in Cancer Therapy. Cancer Discovery, 2014, 4, 873-875.	7.7	28
89	Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib. American Journal of Ophthalmology, 2014, 158, 831-837.e2.	1.7	81
90	Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells. Immunity, 2014, 41, 579-591.	6.6	87

#	Article	IF	Citations
91	Targeting ER stressâ€“induced autophagy overcomes BRAF inhibitor resistance in melanoma. Journal of Clinical Investigation, 2014, 124, 1406-1417.	3.9	352
92	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 3205-3211.	0.8	395
93	The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells. Clinical Cancer Research, 2013, 19, 1784-1794.	3.2	98
94	Autophagy: a targetable linchpin of cancer cell metabolism. Trends in Endocrinology and Metabolism, 2013, 24, 209-217.	3.1	53
95	PUMA: A Puzzle Piece in Chloroquineâ€™s Antimelanoma Activity. Journal of Investigative Dermatology, 2013, 133, 2133-2135.	0.3	6
96	Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2. Cancer Discovery, 2013, 3, 1378-1393.	7.7	197
97	Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy. Clinical Cancer Research, 2013, 19, 2995-3007.	3.2	179
98	The Role of Autophagy in Drug Resistance and Potential for Therapeutic Targeting. , 2013, , 87-116.		0
99	Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome. Clinical Cancer Research, 2012, 18, 370-379.	3.2	264
100	Lys05. Autophagy, 2012, 8, 1383-1384.	4.3	87
101	Autophagy and tumor cell invasion. Cell Cycle, 2012, 11, 3718-3718.	1.3	10
102	Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8253-8258.	3.3	348
103	Survival in BRAF V600â€“Mutant Advanced Melanoma Treated with Vemurafenib. New England Journal of Medicine, 2012, 366, 707-714.	13.9	1,955
104	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
105	Principles and Current Strategies for Targeting Autophagy for Cancer Treatment. Clinical Cancer Research, 2011, 17, 654-666.	3.2	789
106	Autophagy in Tumor Immunity. Science, 2011, 334, 1501-1502.	6.0	29
107	Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma. Clinical Cancer Research, 2011, 17, 3478-3489.	3.2	213
108	Autophagy can contribute to cell death when combining targeted therapy. Cancer Biology and Therapy, 2009, 8, 2097-2100.	1.5	13

#	Article	IF	Citations
109	Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clinical Cancer Research, 2009, 15, 7711-7718.	3.2	104
110	Autophagy-induced tumor dormancy in ovarian cancer. Journal of Clinical Investigation, 2008, 118, 3837-40.	3.9	52
111	Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. Journal of Clinical Investigation, 2007, 117, 326-336.	3.9	983
112	The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment. Clinical Cancer Research, 2007, 13, 7271-7279.	3.2	417
113	Discovery and Characterization of Small Molecule Inhibitors of Autophagy for Cancer Therapy.. Blood, 2006, 108, 2606-2606.	0.6	0
114	The survival kinases Akt and Pim as potential pharmacological targets. Journal of Clinical Investigation, 2005, 115, 2618-2624.	3.9	356
115	Chloroquine Inhibits Autophagy, Enhances p53-Dependent Apoptosis, and Delays Tumor Recurrence in a Mouse Model of B Cell Lymphoma.. Blood, 2005, 106, 2421-2421.	0.6	2